RAMSAY GENERALE DE SANTE SA (GDS.PA) Fundamental Analysis & Valuation

EPA:GDS • FR0000044471

11 EUR
+0.05 (+0.46%)
Last: Mar 3, 2026, 07:00 PM

This GDS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, GDS scores 2 out of 10 in our fundamental rating. GDS was compared to 30 industry peers in the Health Care Providers & Services industry. GDS has a bad profitability rating. Also its financial health evaluation is rather negative. GDS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. GDS.PA Profitability Analysis

1.1 Basic Checks

  • GDS had negative earnings in the past year.
  • GDS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: GDS reported negative net income in multiple years.
  • GDS had a positive operating cash flow in each of the past 5 years.
GDS.PA Yearly Net Income VS EBIT VS OCF VS FCFGDS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • GDS has a worse Return On Assets (-0.79%) than 83.33% of its industry peers.
  • GDS's Return On Equity of -4.72% is on the low side compared to the rest of the industry. GDS is outperformed by 80.00% of its industry peers.
  • GDS's Return On Invested Capital of 2.27% is on the low side compared to the rest of the industry. GDS is outperformed by 76.67% of its industry peers.
  • GDS had an Average Return On Invested Capital over the past 3 years of 1.77%. This is significantly below the industry average of 6.83%.
  • The last Return On Invested Capital (2.27%) for GDS is above the 3 year average (1.77%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.79%
ROE -4.72%
ROIC 2.27%
ROA(3y)-0.29%
ROA(5y)0.37%
ROE(3y)-1.76%
ROE(5y)2.11%
ROIC(3y)1.77%
ROIC(5y)1.41%
GDS.PA Yearly ROA, ROE, ROICGDS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10

1.3 Margins

  • GDS has a Operating Margin of 3.08%. This is in the lower half of the industry: GDS underperforms 60.00% of its industry peers.
  • In the last couple of years the Operating Margin of GDS has grown nicely.
  • GDS's Gross Margin of 77.91% is fine compared to the rest of the industry. GDS outperforms 76.67% of its industry peers.
  • GDS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.08%
PM (TTM) N/A
GM 77.91%
OM growth 3Y23.45%
OM growth 5Y19.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5Y-0.65%
GDS.PA Yearly Profit, Operating, Gross MarginsGDS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

2

2. GDS.PA Health Analysis

2.1 Basic Checks

  • GDS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for GDS remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, GDS has about the same amount of shares outstanding.
  • Compared to 1 year ago, GDS has a worse debt to assets ratio.
GDS.PA Yearly Shares OutstandingGDS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
GDS.PA Yearly Total Debt VS Total AssetsGDS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • Based on the Altman-Z score of 1.01, we must say that GDS is in the distress zone and has some risk of bankruptcy.
  • GDS has a Altman-Z score of 1.01. This is in the lower half of the industry: GDS underperforms 63.33% of its industry peers.
  • The Debt to FCF ratio of GDS is 7.41, which is on the high side as it means it would take GDS, 7.41 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 7.41, GDS is doing good in the industry, outperforming 63.33% of the companies in the same industry.
  • GDS has a Debt/Equity ratio of 3.28. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of GDS (3.28) is worse than 73.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.28
Debt/FCF 7.41
Altman-Z 1.01
ROIC/WACC0.48
WACC4.68%
GDS.PA Yearly LT Debt VS Equity VS FCFGDS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 0.81 indicates that GDS may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.81, GDS is doing worse than 60.00% of the companies in the same industry.
  • GDS has a Quick Ratio of 0.81. This is a bad value and indicates that GDS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GDS has a Quick ratio (0.73) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.73
GDS.PA Yearly Current Assets VS Current LiabilitesGDS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

1

3. GDS.PA Growth Analysis

3.1 Past

  • The earnings per share for GDS have decreased by -0.37% in the last year.
  • The Revenue has been growing slightly by 4.70% in the past year.
  • Measured over the past years, GDS shows a small growth in Revenue. The Revenue has been growing by 6.95% on average per year.
EPS 1Y (TTM)-0.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.93%
Revenue 1Y (TTM)4.7%
Revenue growth 3Y6.82%
Revenue growth 5Y6.95%
Sales Q2Q%3.73%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GDS.PA Yearly Revenue VS EstimatesGDS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2

4. GDS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • GDS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDS.PA Price Earnings VS Forward Price EarningsGDS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 66.67% of the companies in the same industry are more expensive than GDS, based on the Enterprise Value to EBITDA ratio.
  • GDS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GDS is cheaper than 93.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.2
EV/EBITDA 8.22
GDS.PA Per share dataGDS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. GDS.PA Dividend Analysis

5.1 Amount

  • No dividends for GDS!.
Industry RankSector Rank
Dividend Yield 0%

GDS.PA Fundamentals: All Metrics, Ratios and Statistics

RAMSAY GENERALE DE SANTE SA

EPA:GDS (3/3/2026, 7:00:00 PM)

11

+0.05 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-24
Earnings (Next)N/A
Inst Owners39.92%
Inst Owner ChangeN/A
Ins Owners6.67%
Ins Owner ChangeN/A
Market Cap1.21B
Revenue(TTM)5.24B
Net Income(TTM)-54.10M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF 2.2
P/OCF 1.75
P/B 1.06
P/tB N/A
EV/EBITDA 8.22
EPS(TTM)-0.49
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.99
FCFY45.37%
OCF(TTM)6.28
OCFY57.13%
SpS47.49
BVpS10.37
TBVpS-10.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.79%
ROE -4.72%
ROCE 3.09%
ROIC 2.27%
ROICexc 2.45%
ROICexgc 4.65%
OM 3.08%
PM (TTM) N/A
GM 77.91%
FCFM 10.51%
ROA(3y)-0.29%
ROA(5y)0.37%
ROE(3y)-1.76%
ROE(5y)2.11%
ROIC(3y)1.77%
ROIC(5y)1.41%
ROICexc(3y)1.91%
ROICexc(5y)1.51%
ROICexgc(3y)3.58%
ROICexgc(5y)2.81%
ROCE(3y)2.41%
ROCE(5y)1.91%
ROICexgc growth 3Y36.97%
ROICexgc growth 5Y27.82%
ROICexc growth 3Y34.74%
ROICexc growth 5Y25.95%
OM growth 3Y23.45%
OM growth 5Y19.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5Y-0.65%
F-Score3
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 3.28
Debt/FCF 7.41
Debt/EBITDA 6.31
Cap/Depr 32.9%
Cap/Sales 2.72%
Interest Coverage 0.85
Cash Conversion 116.55%
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.73
Altman-Z 1.01
F-Score3
WACC4.68%
ROIC/WACC0.48
Cap/Depr(3y)38.37%
Cap/Depr(5y)42.77%
Cap/Sales(3y)3.25%
Cap/Sales(5y)3.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.93%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.7%
Revenue growth 3Y6.82%
Revenue growth 5Y6.95%
Sales Q2Q%3.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30%
EBIT growth 3Y31.87%
EBIT growth 5Y27.42%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.7%
FCF growth 3Y99.96%
FCF growth 5Y-0.36%
OCF growth 1Y18.22%
OCF growth 3Y38.26%
OCF growth 5Y-1%

RAMSAY GENERALE DE SANTE SA / GDS.PA FAQ

Can you provide the ChartMill fundamental rating for RAMSAY GENERALE DE SANTE SA?

ChartMill assigns a fundamental rating of 2 / 10 to GDS.PA.


What is the valuation status of RAMSAY GENERALE DE SANTE SA (GDS.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to RAMSAY GENERALE DE SANTE SA (GDS.PA). This can be considered as Overvalued.


How profitable is RAMSAY GENERALE DE SANTE SA (GDS.PA) stock?

RAMSAY GENERALE DE SANTE SA (GDS.PA) has a profitability rating of 3 / 10.


Can you provide the dividend sustainability for GDS stock?

The dividend rating of RAMSAY GENERALE DE SANTE SA (GDS.PA) is 0 / 10 and the dividend payout ratio is 0%.